STOCK TITAN
  1. Home
  2. News
  3. DGX

Quest Diagnostics, Inc. - DGX STOCK NEWS

Welcome to our dedicated news page for Quest Diagnostics (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quest Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quest Diagnostics's position in the market.

News
Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test
Rhea-AI Summary
Quest Diagnostics has received Breakthrough Device Designation from the FDA for its AAVrh74 ELISA assay (CDx). The assay is used to detect antibodies to AAVrh74 capsid in human serum and is intended to identify patients eligible for treatment with Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy. Quest and Sarepta have also expanded their collaboration to develop companion diagnostics for Sarepta's gene therapies, including screening assays for muscular dystrophies. Quest will provide clinical lab testing for Sarepta as well.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
News
Making Connections To Care: Quest Supports Inspiring Health Equity Event Hosted by Sisters on the Vineyard
Rhea-AI Summary
Quest Diagnostics supported the Health Empowerment and Wellness event hosted by Sisters on the Vineyard in Martha's Vineyard, Massachusetts, on August 10. The event featured panelist speakers and engaging one-on-one conversations for women of color, providing them with knowledge, resources, and tools to support healthier lives. Accomplished Black female physicians led discussions about breast cancer, mental well-being, nutrition, and more. The event showcased Quest Diagnostics' commitment to health equity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
none
-
News
Quest Diagnostics Declares Quarterly Cash Dividend
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
dividends
News
Inflammation Marker Signifies Increased Mortality Risk, Finds New Study in PLOS ONE
Rhea-AI Summary
DGX: New Study Shows High MPO Levels Linked to Increased Risk of Death from Various Diseases, Quest Diagnostics and MDVIP Research Reveals
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
News
Quest Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX): AD-Detect™ Test for Alzheimer's Disease is now available for consumer purchase on questhealth.com, offering a blood-based biomarker test for assessing beta amyloid protein, a recognized marker of Alzheimer's disease. The test uses plasma from a single blood draw to evaluate levels of amyloid beta proteins, and individuals can purchase it without visiting a doctor first. The test also ensures individuals have access to a continuum of care, with an independent physician network providing clinical oversight of test ordering and results delivery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
News
Quest Diagnostics Reports Second Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) announced second quarter revenues of $2.34 billion, down 4.7% from 2022. Reported diluted EPS was $2.05, up 4.6% from 2022. Full year 2023 revenues are expected to be between $9.12 billion and $9.22 billion. The company experienced nearly double digit revenue growth year over year and made substantial progress improving the profitability of its base business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.99%
Tags
earnings
News
Q4HE Collaborates With Western University of Health Sciences To Support Biopsies Save Lives
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
-
News
Quest Diagnostics Named a 'Best Place To Work for Disability Inclusion' for Sixth Consecutive Year
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
News
Quest Diagnostics Employees Support Healthy NewsWorks Student Journalists
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
News
Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading
Rhea-AI Summary
Quest Diagnostics (DGX) launches novel prostate cancer biomarker test in collaboration with Envision Sciences, aiming to improve diagnosis and grading of prostate cancer. The new tissue-based test service utilizes Envision's proprietary biomarkers and technology to address the clinical need for identifying and differentiating aggressive prostate cancer cases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
Stock DGX logo
Quest Diagnostics, Inc.

NYSE:DGX

DGX Rankings

#619 Ranked by Market Cap
#2771 Ranked by Stock Gains
#1354 Ranked by Dividends

DGX Stock Data

14.27B
109.71M
0.43%
91.73%
2.29%
Medical Laboratories
Health Care and Social Assistance
Link
US
Secaucus

About DGX

quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator